Monday, March 3, 1997
SmithKline Beecham has added two new pieces to its growing drug
discovery platform, last week signing collaborations with Cadus Pharmaceutical Corp. in
functional genomics and Evotec BioSystems GmbH in high throughput screening.
"About four years ago we identified four primary technologies as a
critical base for drug discovery: genomics, bioinformatics, combinatorial chemistry and
ultra-high throughput screening," said John Keller, director of the alliance and
technology group at SmithKline.